MOD-13012 (CTP-IGF-1) Severe primary insulin-like growth factor 1 (IGF-1) deficiency (SPIGFD) results in short stature and increased insulin sensitivity in afflicted patients. We are developing MOD-1301, utilizing our Carboxyl Terminal Peptide (CTP) technology, as an extended release IGF-1 repletion therapy for the treatment of SPIGFD.